Table 1.
Responsiveness to synthetic compounds
| Stimulus | Female | Male | trpc2 −/− | Female (%) | Male (%) | trpc2 −/−(%) |
|---|---|---|---|---|---|---|
| A0225 | 6/42 | 1/64 | 0/21 | 14.3 | 1.6 | 0 |
| A2398 | 1/42 | 5/64 | 0/21 | 2.4 | 7.8 | 0 |
| A2460 | 4/42 | 2/64 | 0/21 | 9.5 | 3.1 | 0 |
| A2534 (50 μm) | 1/42 | 2/64 | 0/21 | 2.4 | 3.1 | 0 |
| A6940 (100 and 50 μm) | 6/42 | 5/182 | 0/21 | 14.3 | 2.7 | 0 |
| A7010 (100 and 50 μm) | 5/42 | 7/182 | 0/21 | 11.9 | 3.8 | 0 |
| A7864 | 2/42 | 8/64 | 0/21 | 4.8 | 12.5 | 0 |
| A8530 | 0/42 | 2/64 | 0/21 | 0 | 3.1 | 0 |
| C4385 | 0/42 | 0/64 | 0/21 | 0 | 0 | 0 |
| C5075 (10 μm) | 0/42 | 0/64 | 0/21 | 0 | 0 | 0 |
| C6905 (50 μm) | 0/42 | 1/64 | 0/21 | 0 | 1.6 | 0 |
| E0588 | 3/42 | 1/64 | 0/21 | 7.1 | 1.6 | 0 |
| E0893 | 0/42 | 2/64 | 0/21 | 0.0 | 3.1 | 0 |
| E1050 | 2/42 | 4/64 | 0/21 | 4.8 | 6.3 | 0 |
| E1100 | 1/42 | 0/64 | 0/21 | 2.4 | 0 | 0 |
| E1103 | 1/42 | 1/64 | 0/21 | 2.4 | 1.6 | 0 |
| E2335 | 0/42 | 0/64 | 0/21 | 0 | 0 | 0 |
| E2732 | 0/42 | 0/64 | 0/21 | 0 | 0 | 0 |
| E4105 (50 μm) | 3/42 | 5/182 | 0/21 | 7.1 | 2.7 | 0 |
| P2135 (50 μm) | 2/42 | 7/182 | 0/21 | 4.8 | 3.8 | 0 |
| P3817 | 9/42 | 11/64 | 0/21 | 21.4 | 17.2 | 0 |
| P3865 (100 and 50 μm) | 1/42 | 4/182 | 0/21 | 2.4 | 2.2 | 0 |
| P8168 | 4/42 | 2/64 | 0/21 | 9.5 | 3.1 | 0 |
| P8200 | 8/42 | 11/64 | 0/21 | 19.0 | 17.2 | 0 |
| Q1570 (cort21S) (100 and 50 μm) | 1/42 | 16/183 | 0/21 | 2.4 | 8.7 | 0 |
| Q1890 | 0/42 | 2/64 | 0/21 | 0 | 3.1 | 0 |
| Q2525 | 2/42 | 2/64 | 0/21 | 4.8 | 3.1 | 0 |
| Q3383 (100 and 50 μm) | 1/42 | 0/182 | 0/21 | 2.4 | 0 | 0 |
| Q3470 (50 μm) | n.t. | 7/118 | n.t. | n.t. | 5.9 | n.t. |
| Q3910 | 3/42 | 6/64 | 0/21 | 7.1 | 9.4 | 0 |
| Q4765 (50 μm) | 0/42 | 1/64 | 0/21 | 0 | 1.6 | 0 |
| Q5545 | 1/42 | 8/64 | 0/21 | 2.4 | 12.5 | 0 |
| ESP1 (0.1 μm) | 3/166 | 0/93 | n.t. | 1.8 | 0 | n.t. |
| rMUP1 (0.1 μm) a | 0/166 | 0/93 | n.t. | 0 | 0 | n.t. |
| AAPDNRETF (1 and 0.1 μm) | 0/35 | 0/104 | n.t. | 0 | 0 | n.t. |
| SYFPEITHI (1 and 0.1 μm) | 0/35 | 0/104 | n.t. | 0 | 0 | n.t. |
| EEARSM (0.1 μm) | n.t. | 0/93 | n.t. | n.t. | 0 | n.t. |
| Acetic acid | 0/35 | n.t. | n.t. | 0 | n.t. | n.t. |
| Arginine | 0/35 | 0/93 | n.t. | 0 | 0 | n.t. |
| Aubepine | 0/69 | 1/117 | n.t. | 0 | 0.9 | n.t. |
| Borneol | 0/69 | 0/117 | n.t. | 0 | 0 | n.t. |
| Butanone | 0/69 | 0/117 | n.t. | 0 | 0 | n.t. |
| Butyric acid | n.t. | 2/93 | n.t. | n.t. | 2.2 | n.t. |
| Butyrophenone | 0/69 | 0/117 | n.t. | 0 | 0 | n.t. |
| p-Cresol | 0/69 | 0/117 | n.t. | 0 | 0 | n.t. |
| Dimethyl disulfide | n.t. | 0/117 | n.t. | n.t. | 0 | n.t. |
| 2,5-Dimethylpyrazine | 0/69 | 0/130 | n.t. | 0 | 0 | n.t. |
| Ethyl acetate | 0/69 | 0/117 | n.t. | 0 | 0 | n.t. |
| Ethyl propionate | 0/69 | 0/117 | n.t. | 0 | 0 | n.t. |
| Ethyl vanilline | 0/69 | 0/117 | n.t. | 0 | 0 | n.t. |
| Eucalyptol | 0/69 | 0/117 | n.t. | 0 | 0 | n.t. |
| β-Farnesene | 0/69 | 0/119 | n.t. | 0 | 0 | n.t. |
| α- and β-Farnesene | 0/69 | 0/117 | n.t. | 0 | 0 | n.t. |
| Fenchone | 0/69 | 0/117 | n.t. | 0 | 0 | n.t. |
| Glutamic acid | 0/35 | 0/106 | n.t. | 0 | 0 | n.t. |
| 2-Heptanone | 0/69 | 0/130 | n.t. | 0 | 0 | n.t. |
| Indole | 0/69 | 0/117 | n.t. | 0 | 0 | n.t. |
| Isoborneol | 0/69 | 0/117 | n.t. | 0 | 0 | n.t. |
| Isobutylamine | 0/69 | 0/130 | n.t. | 0 | 0 | n.t. |
| Isobutyric acid | n.t. | 0/93 | n.t. | n.t. | 0 | n.t. |
| Isovaleric acid | n.t. | 1/93 | n.t. | n.t. | 1.1 | n.t. |
| Methionine | 0/35 | n.t. | n.t. | 0 | n.t. | n.t. |
| Muscone | 0/69 | 0/117 | n.t. | 0 | 0 | n.t. |
| Pentyl acetate | 0/69 | 0/130 | n.t. | 0 | 0 | n.t. |
| Patchone | 0/69 | 0/117 | n.t. | 0 | 0 | n.t. |
| Phenafleur | 0/69 | 0/117 | n.t. | 0 | 0 | n.t. |
| Propionic acid | n.t. | 0/93 | n.t. | n.t. | 0 | n.t. |
The denominator in the responsive electrodes column indicates the number of recording sites on which the given ligand was tested; it includes only active electrodes that responded to at least one stimulus, including 100-fold diluted urine and high potassium. The numerator indicates the number of these electrodes that responded to the specific ligand. Compounds in the first part of the table, labeled with a single letter followed by four digits, are sulfated steroids, except for the glucuronidated steroid Q3470 (supplemental Fig. S2, available at www.jneurosci.org as supplemental material). Nomenclature is from the Steraloids catalog. Compounds were tested at a concentration of 100 μm except where indicated. n.t., Not tested. The references are as follows: AAPDNRETF, SYFPEITHI (Leinders-Zufall et al., 2004); EEARSM (Mucignat-Caretta et al., 1995); ESP1 (Kimoto et al., 2005), rMUP1 (Chamero et al., 2007); acetic acid, butyric acid, propionic acid, isobutyric acid, isovaleric acid (Michael et al., 1971); pentyl acetate (Novotny et al., 1986; Leinders-Zufall et al., 2000; Punta et al., 2002); 2-heptanone (Novotny et al., 1986; Jemiolo et al., 1989; Leinders-Zufall et al., 2000; Sam et al., 2001; Boschat et al., 2002; Punta et al., 2002; Trinh and Storm, 2003); isobutylamine (Punta et al., 2002); 2,5-dimethylpyrazine (Novotny et al., 1986; Leinders-Zufall et al., 2000; Sam et al., 2001; Punta et al., 2002; Trinh and Storm, 2003); α and β farnesenes (Novotny et al., 1990, 1999; Ma et al., 1999; Leinders-Zufall et al., 2000; Sam et al., 2001; Punta et al., 2002); dimethyl disulfide (Singer et al., 1976); arginine, methionine, glutamate, indole, muscone, patchone, p-cresol, eucalyptol, fenchone, borneol, isoborneol, aubepine, butyrophenone, phenafleur (Sam et al., 2001); ethyl acetate, ethyl propionate, ethyl vanilline, butanone (Trinh and Storm, 2003).
aNote that responses reported by Chamero et al. (2007) occurred at concentrations >0.1 μm.